Acute symptomatic seizures secondary to myelin oligodendrocyte glycoprotein antibody-associated disease.


Journal

Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R

Informations de publication

Date de publication:
12 2022
Historique:
revised: 25 09 2022
received: 06 05 2022
accepted: 26 09 2022
pubmed: 29 9 2022
medline: 15 12 2022
entrez: 28 9 2022
Statut: ppublish

Résumé

To report the clinical presentations and outcomes of patients with seizure and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). We retrospectively reviewed the electronic medical records for clinical and paraclinical features among patients with seizures and MOG-IgG (immunoglobulin G) seropositivity. We identified 213 patients with MOG-IgG seropositivity who fulfilled criteria for MOGAD. Seizures attributed to central nervous system (CNS) autoimmunity were observed in 10% of patients (n = 23: 19 children, 4 adults). The majority (n = 19, 83%) had pediatric disease onset. Focal motor seizures were the most common seizure semiology (16/23; 70%). Focal to bilateral tonic-clonic seizures were present in 12 patients (53%), and 3 patients (13%) developed status epilepticus. All patients had features of encephalitis at onset of seizures. Cerebral cortical encephalitis (CCE) was the most common radiological finding (10 unilateral and 5 bilateral cases). Eight of 23 patients (35%) had only CCE, six of 23 patients (26%) had only acute disseminated encephalomyelitis (ADEM), and seven of 23 patients (30%) had features of both. Fifteen patients (65%) had leptomeningeal enhancement. Three patients (13%) had coexistence of N-methyl-d-aspartate receptor (NMDAR) IgG. Only 3 of 23 patients (13%) developed drug- resistant epilepsy. Although the majority had MOGAD relapses (14/23, 60%) had only 5 of 23 patients had recurrence of episodes of encephalitis with associated seizures. Twenty-one of 23 patients (91%) had seizure freedom at last follow-up. MOG-IgG evaluation should be considered in patients who present with encephalitis and focal motor and/or focal to bilateral tonic-clonic seizures, especially pediatric patients with magnetic resonance imaging (MRI) brain findings consistent with CCE, ADEM, or other MOGAD presentations. The majority of these seizures are self-limited and do not require maintenance/chronic antiseizure medications. Although seizure recurrence is uncommon, many patients have MOGAD relapses in the form of encephalitis and optic neuritis.

Identifiants

pubmed: 36168809
doi: 10.1111/epi.17424
pmc: PMC10641900
mid: NIHMS1935946
doi:

Substances chimiques

Myelin-Oligodendrocyte Glycoprotein 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

3180-3191

Subventions

Organisme : NINDS NIH HHS
ID : R01 NS113828
Pays : United States

Informations de copyright

© 2022 International League Against Epilepsy.

Références

Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
pubmed: 26516628
Clin Chem. 2020 Dec 1;66(12):1496-1509
pubmed: 33221892
Neurology. 2021 Sep 28;97(13):e1351-e1358
pubmed: 34389648
Lancet Neurol. 2020 Mar;19(3):234-246
pubmed: 32057303
Neurology. 2019 Mar 12;92(11):e1250-e1255
pubmed: 30728305
Rinsho Shinkeigaku. 2017 Nov 25;57(11):723-728
pubmed: 29070756
Nat Rev Neurol. 2013 Aug;9(8):455-61
pubmed: 23797245
Neurology. 2021 Sep 14;97(11):e1141-e1149
pubmed: 34233939
JAMA Neurol. 2018 Jan 1;75(1):65-71
pubmed: 29131884
JAMA Neurol. 2018 Nov 1;75(11):1355-1363
pubmed: 30014148
Epilepsia. 2022 Mar;63(3):709-722
pubmed: 35032032
J Neuroinflammation. 2018 May 3;15(1):134
pubmed: 29724224
Neuropsychol Rev. 2007 Dec;17(4):413-25
pubmed: 17943448
J Neurol Neurosurg Psychiatry. 2018 Feb;89(2):127-137
pubmed: 29142145
J Neurol Sci. 2018 Sep 15;392:113-115
pubmed: 30048831
Mayo Clin Proc. 2022 Mar;97(3):547-559
pubmed: 34955239
Epilepsia. 2020 Jul;61(7):1341-1351
pubmed: 32544279
JAMA Neurol. 2020 May 1;77(5):648-649
pubmed: 32119057
Neurol Neuroimmunol Neuroinflamm. 2022 Mar 25;9(3):
pubmed: 35338092
Neurol Neuroimmunol Neuroinflamm. 2017 Jan 16;4(2):e322
pubmed: 28105459
Mult Scler. 2021 Jul;27(8):1175-1186
pubmed: 32907470
Mult Scler Relat Disord. 2017 Nov;18:90-92
pubmed: 29141829
Epilepsia. 2017 Dec;58(12):2104-2111
pubmed: 29098690
JAMA Neurol. 2021 Jun 1;78(6):741-746
pubmed: 33900394
J Neurol Sci. 2018 Apr 15;387:170-173
pubmed: 29571858
Eur J Radiol. 2013 Nov;82(11):1964-72
pubmed: 23787273
Curr Opin Neurol. 2020 Jun;33(3):372-380
pubmed: 32374573
Mult Scler Relat Disord. 2020 Jun;41:102011
pubmed: 32163756

Auteurs

Mayra Montalvo (M)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jamal F Khattak (JF)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Vyanka Redenbaugh (V)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jeffrey Britton (J)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Cristina Valencia Sanchez (CV)

Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.

Abhigyan Datta (A)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

Jan-Mendelt Tillema (JM)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

John Chen (J)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.

Andrew McKeon (A)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Sean J Pittock (SJ)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Eoin P Flanagan (EP)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Divyanshu Dubey (D)

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH